General Biotechnology

OpenAI’s “GPT for life sciences” is getting the headlines—but the real question for drug developers isn’t what it can do in a demo. It’s what it changes in the messy, expensive, failure-prone reality of drug development.
That’s the subtext behind the l…

Biosimilar timelines aren’t linear—so why are outreach strategies?
If you’re trying to reach biosimilar manufacturers, you’re probably doing it the hard way: waiting until a patent expiry date is “close enough,” then assuming the commercial and technic…

AI is quietly becoming the new “KOL” in pharma—and most companies aren’t tracking it.
For years, drugmakers have mapped influence the old way: key opinion leaders, conference circuits, advisory boards, and the slow grind of peer-reviewed credibility. B…

Most pharma teams wait until the patent is already dying. That’s why they miss the money.
In drug development, timing is everything—but in licensing, timing is everything squared. The closer a product gets to patent expiry, the more value concentrates …

Drug patent expiry isn’t a single date—it’s a moving target across jurisdictions, regulatory regimes, and legal timelines. And if your portfolio planning still treats it like a one-size-fits-all calendar event, you’re likely making decisions on incompl…

Generic entry is inevitable—unless you build a moat that can’t be copied.
Most investors and operators obsess over the obvious: composition-of-matter patents, branded label exclusivity, and blockbuster timelines. But in the real world, generics don’t…

Your pharmaceutical portfolio may have a time bomb in it—and patent expiration data is the fuse.
If you’re a business leader in pharma, you already know the headline risk: patents expire, generics arrive, margins compress, and growth plans get rewritte…

The 20-year patent is supposed to be a finish line. In pharma, it’s often just the starting gun.
For years, the public narrative has been simple: drug patents last 20 years, and once they expire, competition arrives. But the reality—especially in the U…

Big Pharma doesn’t just “lose” patents—it often rebrands the battlefield.
That’s the core takeaway from DrugPatentWatch’s look at what happens after exclusivity ends: the branded-generic playbook. In plain English, when a patent cliff approaches, the i…

In the high-stakes world of pharmaceuticals, innovation is often viewed through the lens of new drug development, hefty R&D budgets, and regulatory hurdles. But what if the real treasure trove lies not in the next big blockbuster, but in the overlo…